-
RIP kinase Related Products (104)
Related Products (104)
-
VDX-111
0 ImagesCat. No.: HY-156920CAS No.: 158983-23-4VDX-111 is an analog of vitamin D. VDX-111 exhibits cytotoxicity in ovarian cancer cells through upregulation of RIPK1/RIPK3 pathway and induction of necroptosis. VDX-111 promotes expressions of cytokines and exhibits antitumor activity in mouse model.
-
RIP1 kinase inhibitor 8
0 ImagesCat. No.: HY-155804CAS No.: 2226735-54-0RIP1 kinase inhibitor 8 (Compound 77) is a potent and highly selective dihydropyrazole (DHP) RIP1 kinase inhibitor with an IC50 of 20 nM. RIP1 kinase inhibitor 8 prevents necrotic cell death. RIP1 kinase inhibitor 8 shows a favorable pharmacokinetic profile in multiple species.
-
RIPK2-IN-3
0 ImagesCat. No.: HY-124643CAS No.: 1290490-78-6RIPK2-IN-3 (FCG806791773) is a RIPK2 inhibitor. RIPK2-IN-3 inhibits recombinant truncated RIPK2 with an IC50 of 6.39 μM. RIPK2-IN-3 can be used for research of inflammation and cancer.
-
RIPK3-IN-4
0 ImagesCat. No.: HY-156368CAS No.: 2304617-58-9RIPK3-IN-4 (Compound 42) is a RIPK3 inhibitor. RIPK3-IN-4 inhibits HK-2 cell damage, necroptosis and inflammatory responses. RIPK3-IN-4 reduces Cisplatin (HY-17394)- and I/R-induced kidney damage, inflammatory response and necroptosis in acute kidney injury.
-
RIP1 kinase inhibitor 6
0 ImagesCat. No.: HY-153436CAS No.: 2428401-62-9RIP1 kinase inhibitor 6 is a potent and selective RIP1 kinase inhibitor with an IC50 of < 100 nM in human R1P1 kinase assay. RIP1 kinase inhibitor 6 is extracted from patent WO2020103884, example 80.
-
RIPK1-IN-21
0 ImagesCat. No.: HY-157751CAS No.: 3016304-64-3RIPK1-IN-21 (Compound I-5) is an inhibitor of RIPK1 with an EC50 value of 14.8 nM. RIPK1-IN-21 can be used in the research of neurodegenerative, autoimmune, and inflammatory diseases.
-
RIP1 kinase inhibitor 9
0 ImagesCat. No.: HY-163390CAS No.: 3040025-57-5RIP1 kinase inhibitor 9 (compound SY-1) is a selective RIP kinase inhibitor. RIP1 kinase inhibitor 9 effectively suppresses the central inflammatory response induced by epilepsy. RIP1 kinase inhibitor 9 inhibits Z-VAD-FMK (HY-16658B)-induced necroptosis in HT-29 cells with an EC50 of 7.04 nM.
-
RIP3 activator 1
0 ImagesCat. No.: HY-168640CAS No.: 1456899-52-7RIP3 activator 1 (compound C8) is a potent RIP3 activator. RIP3 activator 1 inhibits cell growth. RIP3 activator 1 induces necroptosis through the RIP3/p62/Keap1 signaling pathway. RIP3 activator 1 increases the protein expression of p-MLKL. RIP3 activator 1 induces autophagy. RIP3 activator 1 increases accumulation of LC3-II and p62 protein expression.
-
Fosizensertib
0 ImagesCat. No.: HY-168974CAS No.: 2905377-00-4Fosizensertib is the inhibitor for RIP-1 kinase and can be used in researchs of ulcerative colitis.
-
RIPK1-IN-33
0 ImagesCat. No.: HY-175027RIPK1-IN-33 is a blood-brain barrier-permeable and orally active RIPK1 inhibitor, with an IC50 of 0.115 μM. RIPK1-IN-33 demonstrates remarkable anti-ferroptosis activity, radical scavenging capacity (IC50 = 123.3 μM), and anti-lipid peroxidation effects (IC50 = 9.72 μM). RIPK1-IN-33 markedly reduces cerebral infarction volume and improves neurological function scores in transient middle cerebral artery occlusion (tMCAO) model. RIPK1-IN-33 can be used for the study of ischemic stroke.
-
RIPK2-IN-1
0 ImagesCat. No.: HY-146694CAS No.: 2245820-70-4
-
AZ'320
0 ImagesCat. No.: HY-174820AZ'320 is an ATP-competitive necroptosis (EC50 of 4.9 μM) inhibitor and a RIPK1 (pKD of 5.45) inhibitor. AZ'320 inhibits necroptosis by inhibiting RIPK1 phosphorylation. AZ’320 prevents mortality of the mice and rescues temperature and body weight in SIRS mice models. AZ'320 can be used for researches of cancer and inflammation.
-
RIPK1-IN-15
0 ImagesCat. No.: HY-143480CAS No.: 2755704-34-6RIPK1-IN-15 (Compound 2.5) is a potent inhibitor of RIPK1. RIPK1-IN-15 has the potential for the research neurodegenerative, autoimmune, and inflammatory diseases.
-
RIPK1-IN-18 sulfate hydrate
0 ImagesCat. No.: HY-160216ACAS No.: 2897618-64-1RIPK1-IN-18 sulfate hydrate is a potent RIPK1 inhibitor that can be used in autoimmune diseases research (NZ748385A; compound i).
-
Anticancer agent 284
0 ImagesCat. No.: HY-178937Anticancer agent 284 exhibits cytotoxicity against osteosarcoma cell line (Hos), non-small cell lung cancer cell line (A549), and colon cancer cell line (HCT-116). Anticancer agent 284 can impact the pRIPK3 kinase concentration in the A549 (2.97 pg/mL). Anticancer agent 284 can be used for the study of cancer.
-
RIPK1-IN-26
0 ImagesCat. No.: HY-162928CAS No.: 2252271-96-6RIPK1-IN-26 (Compound 8a) is a potent receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor with cell anti-necroptosis potency. RIPK1-IN-26 demonstrats good metabolic stability and good binding specificity in mice. RIPK1-IN-26 is promising for research of PET imaging probe development and neurodegenerative disorders.
